CURRICULUM VITAE Name: Robert Hon Kwong Mak Address

4/1/14
CURRICULUM VITAE
Name:
Robert Hon Kwong Mak
Address:
Division of Pediatric Nephrology
University of California, San Diego
9500 Gilman Drive, MC 0634
La Jolla, CA 92093-0634
Tel: (858) 822-6713
Fax: (858) 822-6776
Email: [email protected]
ACADEMIC AND CLINICAL APPOINTMENTS
2007-
Professor of Pediatrics (Ladder Series)
Chief, Division of Pediatric Nephrology,
University of California, San Diego (UCSD)
2007-2012
Director, Pediatric Nephrology Fellowship Program, UCSD
2001-2007
Professor of Pediatrics, Oregon Health & Science University
1997-2006
Chief, Division of Pediatric Nephrology, Oregon Health & Science
University
1997-2001
Associate Professor of Pediatrics, Oregon Health & Science University
1992-1997
Assistant Professor of Pediatrics (tenure track), Attending
Pediatric Nephrologist, Stanford University School of Medicine
1986-1992
Assistant Professor of Pediatrics, Attending Pediatric
Nephrologist, Children's Hospital of Los Angeles, University
of Southern California School of Medicine
1983-1986
Lecturer in Pediatric Nephrology, Guy's Hospital Medical
School, University of London, United Kingdom
EDUCATION
1975
1979
1979
1985
MBBS
DCH
MRCP
Ph.D.
University of Hong Kong School of Medicine
Royal College of Physicians (U.K.), Diploma of Child Health
Royal College of Physicians (U.K.), Pediatric Board
University of London, Pediatric Nephrology
1
POSTDOCTORAL TRAINING
Fellowship:
1980-1983
1981
1983
Fellow in Pediatric Nephrology with Sir Cyril Chantler, Guy's
Hospital Medical School, University of London
Research Fellowship with Dr. Ralph DeFronzo, Division of
Nephrology and Endocrinology, Yale University Medical School,
New Haven, CT
Research Fellowship with Dr. Otto Mehls, Division of Pediatric
Nephrology, Heidelberg University, Heidelberg, FRG
Residency:
1976-1978
1979-1980
Resident in Pediatrics, Queen Elizabeth Hospital, Hong Kong
Resident in Pediatrics, Guy's Hospital Medical School, University
of London
HONORS AND AWARDS
1974
1980-1982
1983-1984
1993
1995
1996
1999
2000-2007
2003-2007
2004-2006
2004-2008
2006-2007
2006
2009
2011
2012
Medical Student Prize for Dissertation on "Medical Aspects of
Contraception", University of Hong Kong
Leslie Larkins Fellow in Pediatric Research, University of London
Burroughs Wellcome Lecturer in Pediatrics and Metabolic
Medicine, University of London
Fellow qua Physician of the Royal College of Physicians and
Surgeons of Glasgow, FRCP(Glasgow)
Fellow qua Physician of the Royal College of Physicians of
Edinburgh, FRCP(Edinburgh)
Blue Ribbon Awards for two Outstanding Abstracts,
American Society of Nephrology Annual Meeting
Fellow qua Physician of the Royal College of Physicians of
London, FRCP(London)
Councillor, International Pediatric Nephrology Association
NIH Mid-Career Research Development Award
President, Western Society of Pediatric Nephrology
Chairman, Education Committee
International Pediatric Nephrology Association
Co-chair, Program Committee
American Society of Pediatric Nephrology
Chair, NIH Renal and Urological Small Business Study Section
Co-Chair, 8th International Symposium on Nutrition and Growth in
Chronic Kidney Disease, Oveido, Spain.
Co-Chair, Western Society of Pediatric Nephrology Annual Meeting.
San Diego, CA
Chair, 9th International Symposium on Nutrition and Growth in
Chronic Kidney Disease, San Diego, CA
2
HONORS AND AWARDS (continued)
2012
2013
Mentee Sujana Gunta MD won American Society of Pediatric
Nephrology Trainee Basic Science Research Award.
Mentee Sujana Gunta MD won Pediatric Academic Societies Nathan
Basic Science Research Award
MEDICAL LICENSURE
1987
1987
1997
California License #A043991
DEA License #BM120557
Oregon License #MD24802
SOCIETY MEMBERSHIP
National
1988198819901993199519992007-
Western Society for Pediatric Research
American Society of Nephrology
American Society of Pediatric Nephrology
Society for Pediatric Research
American Society of Transplant Physicians
Western Society of Pediatric Nephrology (Co-founder)
National Kidney Foundation
International
1980198119871987-
Royal College of Physicians and Surgeons, London
Royal Society of Medicine, London
International Society of Nephrology
International Pediatric Nephrology Association
REVIEWER FOR JOURNALS
198919901992199219931994199419941996199619961997199719971999-
Pediatric Nephrology
Kidney International
Pediatric Research
Nephrology, Dialysis, Transplantation
Journal of Adolescent Medicine
Nephron
Pediatrics
Journal of Nephrology
Clinical Nephrology
American Journal of Kidney Diseases
American Journal of Physiology (Renal)
American Journal of Physiology (Endocrinology & Metabolism)
Pediatric Transplantation
Journal of the American Society of Nephrology
Diabetes
3
199920022003200420052006200720072009201120112011-
Journal of Molecular Endocrinology
Journal of American Society of Nephrology
Pediatric Research
Journal of Urology
Nature Clinical Practice Nephrology
New England Journal of Medicine
Peritoneal Dialysis International
Journal of Clinical Endocrinology and Metabolism
Nature reviews, Nephrology
Clinical Endocrinology
American Journal of Nephrology
Nephrology, Dialysis and Transplant
EDITORIAL BOARD
1987-1989
Section editor (uremia) of the International Journal of Pediatric
Nephrology
2003-present Editorial Board, Pediatric Nephrology
2006-2009
Editorial Board, Clinical Journal of the American Society of
Nephrology
2005-2009
Advisory Board, Nature Clinical Practice Nephrology
2004-2010
Consulting Editor, Pediatric Research
2006-2010
Associate Editor, Pediatric Nephrology
2009-present Advisory Board, Nature Reviews Nephrology
2010-present Editorial Board, World Journal of Pediatrics
2011-present Editorial Board, World Journal of Hypertension
2011-present Editorial Board, World Journal of Nephrology
2012
Guest Editor, Pediatric Nephrology
4
COMMITTEES (local)
1986-1987
Committee on Clinical Investigations (Institutional Review Board) Children's
Hospital of Los Angeles, University of Southern California School of
Medicine, Los Angeles, California.
1986-1992
Dialysis and Renal Transplant Committee, Children's Hospital of Los
Angeles, University of Southern California School of Medicine, Los
Angeles, California.
1994-1997
Chairman, Health and Safety Committee, Department of Pediatrics,
Stanford University School of Medicine
1994-1997
Academic Affairs Committee, Department of Pediatrics, Stanford University
School of Medicine
1994-1997
Development and Fundraising Committee, Department of Pediatrics,
Stanford University School of Medicine
2000-2007
Faculty Practice Advisory Committee, Department of Pediatrics, OHSU
2001-2007
Fellowship Training Committee, Department of Pediatrics, OHSU
2002-2007
Promotions and Tenure Committee, Department of Pediatrics, OHSU
2003-2007
Scientific Advisory Committee, General Clinical Research Center, OHSU
2006-2007
Scientific Advisory Committee, Child Health Research Center, OHSU
2007
Chair, Intramural Grant Program, UCSD
2008-2009
Member of Search Committee for Pediatric Pathology Director for
UCSD/RCHSD
2008-2010
UCSD Academic Senate representative, Department of Pediatrics
2009-2010
Member, Quality Improvement Committee, Rady Children’s Hospital
2009-2012
Member of Search Committee for Pediatric Hematology Oncology Faculty
for UCSD/RCHSD
2009-2012
Chair of Search Committee for Pediatric Clinical Research Director for
UCSD/Rady Childrens’s Hospital
2009-present Member, Billings and Compliance Committee, Rady Children’s Hospital
5
NATIONAL/INTERNATIONAL COMMITTEES/MEETINGS
1990-1992
External Monitoring Committee for NIH R01 grant to Dr. Isidro Salusky,
UCLA "Intraperitoneal calcitriol in the treatment of renal osteodystrophy in
children on peritoneal dialysis,"
1993-1994
Ad Hoc review committee for NIDDK RO1 grant application. "In versus
outpatient treatment of urinary tract infections in children under two."
1997
Chairman, Pediatric Nephrology Platform Session
Society for Pediatric Research Annual Meeting
1997
Professional Advisory Board, National Kidney Foundation of Oregon
and SW Washington
1997
Chairman, Northern California Pediatric Nephrology Symposium
1998
Chairman, Northwest Pediatric Nephrology Educational Series
1999
1999
Keynote speaker, Asian Pediatric Nephrology Symposium, Hong Kong
Session Chairman, International Symposium on Growth in Renal Failure
International Pediatric Nephrology Association
1999
Keynote Speaker, International Pediatric Nephrology South America
Congress, Valencia, Venezuela
1999
Chairman, Western Pediatric Nephrology Symposium, Portland.
2001
Organizing Committee Member, Western Pediatric Nephrology Symposium,
San Francisco.
2001
Organizing Committee Member, International Developmental Renal
Physiology Workshop, Victoria, Canada
2001
Organizing Committee Member, International Pediatric Nephrology
Association Congress, Seattle.
2001
Reviewer for abstracts for “Genetic and molecular basis of renal disease”
International Pediatric Nephrology Association Congress, Seattle.
2001
Chairman, session on “Development of uroepithelium and bladder.”
International Developmental Renal Biology Workshop, Victoria, Canada.
2002
Chairman, Pediatric Nephrology Platform Session
Society for Pediatric Research Annual Meeting
2002
Reviewer for Pediatric Nephrology Abstracts
Society for Pediatric Research Annual Meeting
6
2002-2008
Councillor, International Pediatric Nephrology Association.
2002-2008
Grant Review Committee A, March of Dimes Foundation
2004-
Research Committee, American Society of Pediatric Nephrology
2002-07
Steering Committee Member, NIH U01 DK-02-013 Multi-Center Grant
“Focal Segmental Glomerulosclerosis in Children and Young Adults.”
2002-07
Co-Chair, Subcommittee on ancillary studies, NIH U01 Multi-Center Grant
“Focal Segmental Glomerulosclerosis in Children and Young Adults.”
2003
Member, NIH NIDDK Task Force on Primary vesico-ureteral reflux.
2003
Member, NIH Study Section on Program Project Grant on “Podocyte biology
in health and disease.”
2003
Co-chairman, session on “Genomics and Proteomics in Pediatric
Nephrology Research”, American Society for Pediatric Nephrology Annual
Meeting, Seattle.
2003
Co-chairman, session on “New Tools for Biological Discovery”
American Society of Nephrology Annual Meeting, San Diego
2003-2009
Steering Committee Member, NIH U01 Multi-Center Grant “Cohort study on
Chronic Kidney Disease in Children “
2003-2010
Chairman, Committee on Progression of CKD, NIH U01 Multi-Center Grant,
“Cohort study on Chronic Kidney Disease in Children“
2004
Member, Scientific Organizing Committee
International Symposium on Growth and Metabolism in Renal Disease,
Heidelberg, Germany
2004
Chairman, session on “Nutrition in Renal Failure”
International Congress of Pediatric Nephrology, Adelaide, Australia.
2002
Grant Review Committee, American Society of Nephrology
2004-2006
President, Western Society of Pediatric Nephrology
2004-2009
Chairman, Educational Committee, International Pediatric Nephrology
Association
2005
Chairman, Pediatric Nephrology Session, World Congress of Nephrology,
Singapore.
2005
Reviewer abstracts ASN annual meeting
7
2005
Chairman, Session on Genomics and Proteomics ASN annual meeting
2006
Co-Chair, Symposium on Inflammation and Uremic Pathophysiology
ASPN/PAS annual meeting
2006
Ad hoc member, NIH Pathobiology of Kidney Disease Study Section
2006
Ad hoc member, NIH Urologic and Kidney Development and Genitourinary
Diseases Study Section
2006
Ad hoc member, NIH Cellular and Molecular Biology of the Kidney Study
Section
2006
Chair, NIH Renal and Urological Small Business Study Section
2006-2007
Co-chair, Program Committee, ASPN/PAS Annual Meeting
2007
Visiting Professor, Renal Division, Baylor University
2007
Co-chair, Sympsoium on Endothilial dysfunction in renal disease.
ASPN/PAS Annual Meeting, Toronto, 2007
2007
Co-chair, Symposium on Genomics and Proteomics in Pediatric Nephrology
International Congress of Pediatric Nephrology, Budapest, Hungary
2008
Chair, Symposium on Bone and Mineral Disorder in Chronic Kidney Disease
PAS/ASPN Annual Meeting, Honolulu.
2009
Chair, Symposium on Obesity and Chronic Kidney Disease.
PAS/ASPN Annual Meeting, Baltimore.
2009
Co-Chair, 8th International Symposium on Nutrition and Growth in Chronic
Kidney Disease, Oveido, Spain.
2010-pres
Professional Advisory Board, Cystinosis Research Foundation 2010 to
present
2011
Co-chair, Western Society of Pediatric Nephrology Annual Meeting, San
Diego, CA.
2011
Chair, Abstract Review Committee, Bone Mineral Metabolism, American
Society of Nephrology Annual Meeting, Philadelphia, PA.
2011
Chair, Session on Advances in PTH and Vitamin D metabolism. American
Society of Nephrology Annual meeting, Philadelphia, PA.
8
2012
Chair, 9th International Symposium on Nutrition and Growth in Chronic
Kidney Disease, San Diego, CA.
2012
Member, abstract review committee, American Society of Nephrology
Annual Meeting, San Diego.
2012-pres
Chair, Data and Safety Monitoring Board on Genzyme’s ongoing study
entitled “A 2-week placebo-controlled, fixed dose period followed by a 6month, single-arm, open-label, dose titration period study to investigate the
efficacy and safety of sevalamar carbonate in hyperphosphatemic pediatric
patients with chronic kidney disease”
2013
Member, abstract review committee, International Pediatric Nephrology
Association Congress, Shanghai, China
2013
Chair, International Pediatric Nephrology Association Congress, Congress,
Shanghai, China, Symposium on “Inflammation in chronic kidney disease”.
RESEARCH INTERESTS
1.
GH and IGF-I signal transduction in uremia
2.
Biomarkers and candidate genes for reflux nephropathy.
3.
Biomarkers for progression of chronic kidney disease in children.
4.
Cytokine signaling and cachexia of uremia.
5.
Central mechanism of uremic osteodystrophy
6.
Cardiovascular complications of chronic kidney disease
7.
Epigenetics and progression of chronic kidney disease
8.
Genetic regulation of weight and height in chronic kidney disease
GRANTS
1.
National Institutes of Health Biomedical Research Support Grant. Principal
Investigator. "Insulin metabolism in uremia.” July 88-June 91.
2.
American Heart Association "Grant-in-aid" Principal Investigator, "Regulation of the
biosynthesis of Na-K ATPase - subunits in the pathogenesis of hypertension and
insulin resistance in uremia.” November 92-January 94.
3.
Genentech Inc. Clinical Grant. Principal Investigator, "Effect of growth hormone on
renal osteodystrophy and glucose metabolism in children with growth failure from
chronic renal failure.” September 93-December 94.
9
4.
Amgen, Inc. Clinical Grant. Principal Investigator, "Effect of human recombinant
erythropoietin on protein, carbohydrate and lipid metabolism in pediatric patients on
dialysis.” September 91-December 95.
5.
Genentech Foundation Clinical Grant. Principal Investigator, "Effect of growth
hormone on insulin, IGF-I and bone mineral metabolism in children with growth
failure from chronic renal failure.” September 94-October 96.
6.
Genentech Foundation Basic Science Grant. Principal Investigator, "Molecular
mechanisms of growth failure in uremia.” July 96-June 97.
7.
National Kidney Foundation Research Grant.
resistance in uremia." June 96-June 97.
8.
Oregon Medical Research Foundation Grant.
regulation in uremia.” July 98-June 99.
9.
Genentech Foundation Laboratory Based Clinical Research Grant. Principal
Investigator, "Circulating inhibitors of growth in uremia." July 97-December 98.
10.
National Kidney Foundation Research Grant. Principal Investigator "Candidate
gene(s) for reflux nephropathy.” July 99-June 00.
11.
Dickinson Foundation Research Grant. Principal Investigator “Molecular diagnostic
and therapeutic approach to urinary tract infections in children.” July 00-June 01.
12.
Friends of Doernbecher Foundation Research Grant. Principal Investigator, “Protein
biomarkers for progression of chronic renal disease.” July 00-June 01.
13.
Baxter Inc. Extramural Grant Award. Principal Investigator, "IGF-I gene regulation in
uremia." February 99-January 02.
14.
Pharmacia Inc. Extramural Grant Award. Principal Investigator, “Growth hormone
resistance in chronic renal failure.” July 00-June 03.
15.
Friends of Doernbecher Foundation Research Grant. Principal Investigator, “Protein
biomarkers for progression of chronic kidney disease.” July 03-June 04.
16.
National Institutes of Health. NIDDK R01 Award (DK50780) Principal Investigator,
"Growth retardation in chronic renal failure." May 97-April 04.
17.
Baxter Inc. Renal Discovery Program: Extramural Grant Award. Principal
Investigator, “Cytokine signaling and cachexia of uremia.” July 03-June 06.
18.
National Institute of Health, NIDDK U01 DK-02-013 Co-principal Investigator “Focal
Segmental Glomerulosclerosis in Children and Young Adults.” October 02September 07.
10
Principal Investigator, "IGF-I
Principal Investigator “IGF-I gene
19.
National Institute of Health, NIDDK K24 DK059475 Principal Investigator. Mid
Career Research Development Award. “Molecular analysis of Vesicoureteric Reflux.”
July 03-June 08.
20.
National Institute of Health, NIDDK U01 DK-03-012. Co-principal Investigator
“Cohort study of chronic kidney disease in children.” October 03-September 08.
21.
National Institute of Health, NIDDK R21 DK059475. Principal Investigator. “Urine
biomarkers for steroid resistant nephrotic syndrome.” September 04-August 07.
22.
National Institute of Health NIDDK U01 DK-02-013 supplement. Principal
Investigator. “Urine biomarkers for obesity associated FSGS.”
October 06September 08.
23.
Collins Medical Trust Extramural grant. Principal Investigator. “Novel therapy for
uremic cachexia.” February 06-January 07.
24.
Satellite Healthcare Inc Extramural Research grant. Principal Investigator. “Energy
homeostasis and cachexia in uremia.” July 07-June 10.
25.
Abbott ExtenD Extramural Research Grant. Principal Investigator. “The therapeutic
effect of vitamin D on cardiovascular disease and survival in chronic kidney
disease.” September 09-August 12.
26.
Cystinosis Research Foundation Research Grant. Principal Investigator. “Energy
homeostasis and muscle wasting in nephropathic cystinosis.” January 10-December
11.
27.
Bioline Inc Extramural Research Grant. Principal Investigator. “Impact of leptin
inhibitor on uremic cachexia.” July 11-June 12.
28.
National Institute of Health, NIDDK U01 DK-03-012. Co-principal Investigator
“Cohort study of chronic kidney disease in children.” October 08-September 13.
29.
National Institute of Health, R13. Principal Investigator. International Symposium on
Growth and Nutrition in Chronic Kidney Disease. April 12-March 13.
30.
Abbott Inc Extramural Research Grant. Principal Investigator. “The impact of
atrasentan on protenuria, disease progression, cardiovascular complications and
survival in a mouse model of diabetic nephropathy with chronic kidney disease.
June 12-May 14.
31.
Cystinosis Research Foundation Research Grant. Principal Investigator. “Vitamin D
and muscle wasting in nephropathic cystinosis. July 12-June 14.
32.
National Institute of Health, Muscle Center Grant R24HD050837 Pilot Project
Principal Investigator “The impact of vitamin D on muscle wasting in chronic kidney
disease” June 12 to May 14.
11
33.
National Institute of Health, NIDDK U01 DK-03-012. Co-principal Investigator
“Cohort study of chronic kidney disease in children.” October 13-September 18.
34.
Cystinosis Research Foundation Research Grant. Principal Investigator.
“Inflammation and inflammasome signaling in nephropathic cystinosis. February 14January 16.
12
TRAINEES
Current Fellows
Celina Cepeda, MD
Elliot Perens, MD, PhD
Dean Nourbakhsh, DO
Past Fellows
James Tee, MD
Sun-Young Ahn
Anna Mathew, MD
Caitlin Carter, MD
Sujana Gunta, MD
07/13-present
07/11-present
07/12-present
07/03-06/08 Asst Professor, University of Calgary, Canada
11/05-10/08 Asst Professor, Washington University School
of Medicine, St. Louis, MO
07/07-07/11 Clinical Lecturer, University of Michigan
07/08-12/12 Physician, Scripps La Jolla, Rady CH
07/10-09/13 Physician, Tri-City Medical, Rady CH
Supervisor/Adviser for the following visitors:
Kyung Paik, MD, PhD
03/09-02/10 Assoc Professor, Seoul Natl University, Seoul, Korea
Uwe Querfeld, MD
05/09-09/09 Professor, Charité University Hospital,
Berlin, Germany
Qian Shen, MD
08/10-10/10 Registrar, Children’s Hospital, Shanghai, China
Jianying Zhan, MD
04/10-11/10 Pediatrician, Zhejiang Univ, Hangzhou, China
Wei Ding, MD
05/11-07/11 Fellow, Fudan University, Shanghai, China
Shiping Li, MD
02/13-07/13 Pediatrician, Yangzhou, Jiangsu, China
Wei Ding, MD
04/14-03/16 Pediatrician, Fudan University, Shanghai, China
Research Scientist:
Wilson Cheung, PhD
05/07-present
Residents:
2007
Julie Talmasano
Sarah Maifield
Erin Fortune
Carol Budzik
Suresh Rangarajan
Corrie Stofcho
Katy Johnston
Jenna Griggs
Johanna Chang
Sheila Laksana
Greg Montoya
Tina Ho
Helen Harvey
Anya Freedman
May 3-30
May 31-June 13
May 31-June 30
June 14-30
Jul 1-25
Jul 12-18
Jul 26-Aug 8
Aug 9-22
Aug 23-Sept 19
Sept 20-Oct 3
Oct 4-17
Oct 18-Nov 14
Nov 30-Dec 12
Dec 13-26
13
2008
Rachael Zweig
Katy Johnston
Erin Papenfuss
David Shyr
Jenna Griggs
Norris Vivatrat
Sofia Moreno
Annemarie Selaya
Kat Freese
Katherine Stumpf
Patrick McVey
Robin Bareng
Chris Sullivan
Alexandra Smith
Feb 7-20
Mar 20-Apr 2
Apr 4-16
May 1-28
May 29-June 11
May 29-June 11
July 1-9
July 1-23
July 10-23
July 24-Aug 6
July 24-Aug 20
Aug 21-Sept 17
Sept 18-Oct 15
Oct 30-Nov 12
2009
Jennie Fuller
Grant Keeney
Shelton Viola
David Del Bello
Robin Bareng
Katie Good
Megan Browning
Lori Broderick
Monique Mayo
Mar 19-Apr 1
Apr 16-29
May 28-June 24
Jul 1-22
Jul 9-22
Sept 17-Oct 14
Oct 15-Nov 11
Nov 26-Dec 9
Dec 10-Jan 6
2010
Ben Frischhertz
Grant Keeney
Loren Sacks
Quoc Nguyen
Jessica Gordon
Kelly McCarthy
Ben Blevins
Lori Broderick
Jennifer Shepherd
Manju Samant
Erin Toole
Katie Wilde
Lauren Hackett
Steve Reeves
Tina Udaka
Dani Monteil
Brian Williams
Erin Blevins
Jan 7-20
Feb 18-Mar 3
Feb 18-Mar 3
Feb 18-Mar 3
Apr 1-28
Apr 29-May 13
June 3-24
June 10-30
June 10-30
June 24-Jul 21
Jul 1-21
Jul 8-Aug 2
Aug 5-Sept 1
Sept 2-15
Sept 30-Oct 13
Oct 14-Nov 25
Oct 28-Nov 10
Dec 9-Jan 5
14
2011
Kris Kazlauskas
Adelaine Trask
Stacy Dodt
Erin Toole
Kimberly Montez
Melissa Moreles
Dan Sisti
Megan Klenow
Mar 31-Apr 27
May 12-25
May 26-June 23
June 24-30
Aug 26-Sept 8
Sept 23-Oct 6
Nov 18-Dec 15
Dec 16-29
2012
Melissa Moreles
Natalie Gilman
Kate Scott
Feb 10-23
Jul 26-31
Dec 14-17
2013
Lauge Farnas
Whitney Law
Jeanne Caroll
Gibran Pierluissi-Jovet
Denise Carranza
Nicole Bendin
Sri Grevich
Jan 11-24, May 17-30
Feb 18-21
June 14-30
Aug 1-14
Aug 9-22
Aug 23-Sept 19
Nov 29-Dec 12
2014
Jefferson Jones
Lawrence Ma
Amy Sweigart
Jan 10-23
Jan 10-Feb 6
Mar 17-Apr 2
Medical Students:
2007
Karen Frankwich
John Huang
Neetha Vilasagar
Eric Beard
Hanna Neumeier
Jul 23-Aug 19
Sept 17-Oct 14
Oct 15-Nov 11
Oct 15-Nov 11
Nov 12-Dec 9
2008
Corrina Schwenke
Jan 7-Feb 3
2009
Yahn‐Yir Chau
Emily McDonnel
Mar 30-Apr 26
Oct 19-Nov 15
15
2010
Jody Lin
Erin Kim
Sept 27-Oct 24
Oct 24-Nov 21
2011
Wei Ding
Burak Ucpinar
Deniz Alis
Wiata Weeks
Apr 1-July 31
Aug 1-25
Aug 8-30
Sept 26-Oct 23
2012
Simon Oberle
Emily Rudomin
Carlos Montes
Mar 26-Apr 22
Sept 24-Oct 21
Nov 19-Dec 17
2013
Phillip Hartman
Jillian Scambia
Carolin Staude
Rachel Marano
Feb 25-Mar 24
Mar 25-Apr 21
May 20-June 16
Sept 9-Oct 6
2014
Po-Chao Chen
Francisco Santoscoy
Jan 6-31
Mar 3-30
16
PUBLICATIONS
1.
Candy, DC, Leung TS, Mak RH et al. A fimbrial antigen mediating haemag-glutination of
E. Coli from children. FEMS LETT (Microbiology)15:325-329, 1982.
2.
Haycock GB, Al-Dahhan J, Mak RH, Chantler C. The effect of indomethacin on clinical
progress and renal function in cystinosis. Archives of Diseases in Childhood 57:934939, 1982.
3.
Mak RH, Al-Dahhan J, Azzopardi D, Bosque M, Chantler C, Haycock GB. Measurement
of glomerular filtration rate in children after renal transplantation. Kidney International
23:410-413, 1983.
4.
Mak RH, Haycock GB, Chantler C. Glucose intolerance in children with chronic renal
failure. Kidney International 24 (Suppl 15):S22-S26, 1983.
5.
Mak RH, Turner C, Haycock GB, Chantler C. Secondary hyperparathyroidism and
glucose intolerance in children with uremia. Kidney International 24 (Suppl 16):S128S133, 1983.
6.
Mak RH, Bettinelli A, Turner C, Haycock GB, Chantler C.
The influence of
hyperparathyroidism on glucose metabolism in uremia. Journal of Clinical Endocrinology
and Metabolism 60:229-233, 1985.
7.
Mak RH, Turner C, Powell H, Thompson T, Haycock GB, Chantler C. Suppression of
secondary hyperparathyroidism in children with uremia with high dose phosphate
binders: CaCO3 Vs Al(OH)3. British Medical Journal 291:623-627, 1985.
8.
Mak RH, Chantler C. Glucose intolerance in uremia: Effect of hemodialysis and
continuous ambulatory peritoneal dialysis, in CAPD in Children. Edited by Fine RN,
Scharer K, Mehls O. Springer Verlag, Berlin, Heidelberg, New York, Tokyo. pp. 58-68,
1985.
9.
Mak RH, Turner C, Thompson T, Haycock GB, Chantler C. The effect of dietary protein
restriction and amino acid/keto acid supplements on glucose metabolism in uremic
children. Journal of Clinical Endocrinology and Metabolism 63:985-989, 1986.
10. Tamanaha K, Mak RH, Rigden S, Turner C., Haycock GB, Chantler C. Long term
suppression of hyperphosphatemia and hyperparathyroidism by high dose phosphate
binders in uremic children. Pediatric Nephrology 1(2):145-149, 1987.
11. Mak RH, Turner C., Thompson T, Haycock GB, Chantler C. Glucose metabolism in
children with uremia: Effect of dietary protein and phosphate. Kidney International 32
(Suppl 22):S206-S209, 1987.
17
12. Turner, Compston J, Mak RH, Vedi S, Mellish P, Haycock GB, Chantler C. Bone
turnover and 1,25 dihydroxycholecalciferol during treatment with phosphate binders.
Kidney International 33:989-995, 1988.
13. Mak RH. Glucose disposal in uremic children. Pediatric and Adolescent Endocrinology
20:90-100, 1989.
14. Mak RH. Carbohydrate metabolism in uremia. Pediatric Nephrology 3:201-208, 1989.
15. Mak RH. Insulin secretion in uremia: Effect of parathyroid hormone and vitamin D
metabolites. Kidney International 36 (Suppl 27):S227-S231, 1989.
16. Friedman AL, Heiliczer JD, Gundberg CM, Mak RH, Boineau FG, McEnery PT, Chan
JCM. Serum osteocalcin concentrations in children with chronic renal insufficiency who
are not undergoing dialysis. Journal of Pediatrics 116:S55-S59, 1990.
17. Buckland-Wright C, Spring MW, Mak RH, Turner C, Compston J, Vedi S, Haycock GB,
Chantler C. Quantitative microfocal radiography of children with renal osteodystrophy:
Comparison with laboratory and histological finding. British Journal of Radiology 63:609614, 1990.
18. Karpati R, Mak RH, Lemley KV. Hypercalcemia, hypertension and acute renal failure.
Child Nephrology and Urology 11:215-219, 1991.
19. Mak RH. 1,25 dihydroxycholecalciferol corrects glucose intolerance in hemodialysis
patients. Kidney International 41:1049-1054, 1992.
20. Mak RH.
Amelioration of hypertension and insulin resistance
dihydroxycholecalciferol in uremia. Pediatric Nephrology 6(4):345-348, 1992.
by
1,25
21. Mak RH, DeFronzo RA. Glucose and insulin metabolism in uremia. Nephron 61(4):377382, 1992.
22. Mak RH, Wong JH. The vitamin D/parathyroid hormone axis in the pathogenesis of
hypertension and insulin resistance in uremia. Mineral Electrolyte Metabolism 18:156159, 1992.
23. Mak RH, Kurtin S, Alon U. Renal hyperphosphatemia, in Phosphate in Pediatric Health
and Disease. Edited by Alon U, Chan JCM. CRC Press, Boca Raton, Florida. pp 235256, 1993.
24. Mak RH. Early history of renal rickets. American Journal of Nephrology 13:293-297,
1993.
25. Mak RH. Renal disease, insulin resistance and glucose intolerance. Diabetes Reviews
2:19-28, 1994.
18
26. Mak RH, Haycock GB, Chantler C. Insulin and growth in chronic renal failure. Pediatric
Nephrology 8:309-312, 1994.
27. Mak RH. Insulin secretion and growth in uremia. Pediatric Research 38: 379-383, 1995.
28. Mak RH. Insulin resistance in uremia: Effect of dialysis modality. Pediatric Research
40:304-308, 1996.
29. Mak RH. The effect of erythropoietin on insulin, amino acid and lipid metabolism in
uremia. Journal of Pediatrics 129(1):97-104, 1996.
30. Mak RH, Pak Y. End-organ resistance to growth hormone and IGF-I in epiphyseal
chondrocytes of uremic rats. Kidney International 50:400-406, 1996.
31. Mak RH. Insulin resistance but IGF-I sensitivity in chronic renal failure.
Journal of Physiology 271(40):F114-F119, 1996.
American
32. Mak RH, Mehls O. Insulin-like growth factor-I action on glucose transport in acute renal
failure American Journal of Physiology 271:F440-F445, 1996.
33. Mak RH. Correction of anemia by erythropoietin reverses insulin resistance and
hyperinsulinemia in uremia. American Journal of Physiology 270(39):F839-F894, 1996.
34. Alfrey EJ, Conley SB, Tanney DC, Mak R, Salvatierra O. Use of an augmented urinary
bladder can be catastrophic in renal transplantation. Transplantation Proceedings
29:154-155, 1997.
35. Salvatierra O, Tanney DC, Mak R, Alfrey E, Lemley K, Mackie F, So S, Hammer GB,
Krane EJ, Conley SB.
Pediatric renal transplantation and its challenges.
Transplantation Reviews 11:51-69, 1997.
36. Salvatierra O, Alfrey E, Tanney DC, Mak R, Hammer GB, Krane EJ, So SK, Lemley K,
Dafoe DC, Orlandi PD, Page LP, Conley S. Superior outcomes in pediatric renal
transplantation. Archives of Surgery 132:842-849, 1997.
37. Alfrey E, Salvatierra O, Tanney D, Mak R, Hammer G, Orlandi P, Conley S. Bladder
augmentation can be problematic with renal failure and transplantation: Report of 10
cases. Pediatric Nephrology 11:672-675, 1997.
38. Mak RH. 1,25 vitamin D3 corrects insulin and lipid abnormalities in uremia. Kidney
International 53:1353-1357, 1998.
39. Mak RH. Effect of metabolic acidosis on insulin action and secretion in uremia.
Kidney International 54:603-607, 1998.
40. Mak RH. Insulin, branched-chain amino acids and growth failure in uremia.
Nephrology 12:637-642, 1998.
19
Pediatric
41. Mak RH. Metabolic effects of erythropoietin in uremic patients on peritoneal dialysis.
Pediatric Nephrology 12:660-665, 1998.
42. Mak RH. Effect of metabolic acidosis on branched-chain amino acids in uremia.
Pediatric Nephrology 13:319-322, 1999.
43. Mak RH. Effect of metabolic acidosis on hyperlipidemia in uremia.
Nephrology 13:891-893, 1999.
Pediatric
44. Salvatierrra O, Tanney D, Mak R, Alfrey E, Lemley K, Mackie F, So S, Hammer G, Krane
Ej, Conley SB. Transplante renal pediatrico y sus retos. Tranplante de Organos, 2 nd
edition, Eds Santiago-Delpin EA and Ruiz-Speare JO, JGH Editores, pp 688-705, 1999.
45. Mak RH. Impact of end-stage renal disease and dialysis on glycemic control. Seminars
in dialysis. 13(1):4-8, 2000.
46. Mak RH, Huey-Ju Kuo. Primary vesico-ureteral reflux: emerging insights from molecular
and genetic studies. Current Opinions in Pediatrics 15:181-185, 2003.
47. Chan JCM, Mak RH. Acid-base homeostasis. In Pediatric Nephrology eds Avner E,
Harman W & Niadut P. 5th Edition, Lippincot, Williams & Wilkins, pp 189-208, 2004.
48. Mak RH, Chang SL, Pak YK. Growth impairment of primary chondrocyte cells by serum
of rats with chronic renal failure. Exp Mol Med 36:243-250, 2004.
49. Mak RH, Chang SL, Draksharpu A, Pak YK. Gene expression in uremic left ventricular
hypertrophy: effects of hypertension and anemia. Exp Mol Med 36:251-258, 2004.
50. Mak RH, Cheung W, Cone R, Marks DL. Orexigenic and anorexigenic mechanisms in
the control of nutrition in chronic kidney disease. Pediatric Nephrology 20:427-431,
2005. Impact factor 2.9
51. Cheung W, Marks DL, Yu X, Cone R, Mak RH. Role of leptin and melanocortin signaling
in uremia-associated cachexia.. Journal of Clinical Investigation 115:1659-1665, 2005.
Impact factor 15.4
52. Mak RH, Cheung W, Cone R, Marks DL. Leptin and inflammation-associated cachexia
in chronic kidney disease. Kidney International 69:794-797, 2006. Impact factor 7.9
53. Mak RH, Kuo HJ. Pathogenesis of urinary tract infection: An Update. Current Opinions
in Pediatrics 18:148-152, 2006. Impact factor 2.6
54. Mak RH, Rotwein P. Myostatin and IGF-I in the pathogenesis of uremic sarcopenia: the
Yin and Yang of muscle mass regulation. Kidney International 70:410-412, 2006. Impact
factor 7.9
55. Mak RH, Cheung W, Cone R, Marks DL. Cytokine and adipokine signaling in uremic
cachexia. Nature Clinical Practice Nephrology 2:527-534, 2006. Impact factor 7.9
20
56. Furth SL, Cole SR, Mimms MM, Kaskel F, Mak R, Schwartz G, Wong C, Munoz A,
Warady BA. Design and Methods of the chronic kidney diseases in children (CKiD)
prospective Cohort Study. Clinical Journal American Society Nephrology 1:1006-1015,
2006. Impact factor 5.2
57. Mak RH, Kuo HJ, Cheung W. Animal models of obesity-associated chronic kidney
disease. Advances in Chronic Kidney Disease 13:374-385, 2006. Impact factor 2.1
58. Mak RH. Can plasma iohexol disappearance be used to measure GFR in children with
chronic kidney disease? Nature Clinical Practice Nephrology 2:608-609, 2006. Impact
factor 7.9
59. Mak RH, Cheung W, Cone R, Marks DL. Energy homeostasis and cachexia in chronic
kidney disease. Pediatric Nephrology 21:1807-1814, 2006. Impact factor 2.9
60. Wong C, Mak RH. Chronic Kidney Disease. Clinical Pediatric Nephrology 2nd Edition.
eds Kher K, Makker SP, Schnaper HW, Taylor & Francis. 2006.
61. Mak RH, Cheung W. Mechanisms of cachexia. In Adipokines in health and disease.
Eds Fantucci G 2006.
62. Mak RH Chronic kidney disease in children: State of the Art. Pediatric Nephrology
22:1687-1688, 2007. Impact factor 2.9
63. Mak RH, Proesmans W, Trachtman H. Teaching articles: a new goal of the journal.
Pediatric Nephrology 22:24-25, 2007. Impact factor 2.9
64. Mak RH Cheung W. Cachexia in chronic kidney disease: Role of inflammation and
neuropeptide signaling. Current Opinions in Nephrology and Hypertension 16:27-31,
2007. Impact factor 4.0
65. Mak RH, Cheung W. Ghrelin in chronic kidney disease: too much or too little?
Peritoneal Dialysis International 27:51-55, 2007. Impact factor 2.1
66. Mak RH, Secker D. Nutritional Challenges in chronic kidney disease. In Practical
Pediatric Nephrology, Eds Geary D, Schaefer F, 2007.
67. Wahba I, Mak RH. Obesity and obesity-initiated metabolic syndrome: Mechanistic links
to chronic kidney disease. Clinical Journal American Society of Nephrology 2:550-562,
2007. Impact factor 5.2
68. Cheung W, Kuo HJ, Markison S, Chen C, Foster AV, Marks DL, Mak RH. Peripheral
administration of the melanocortin-4 receptor antagonist NBI-12i ameliorates uremiaassociated cachexia in mice. Journal of the American Society of Nephrology 18:25172524, 2007. Impact factor 7.9
69. Mak RH, Cheung W. Therapeutic strategy for cachexia in chronic kidney disease. Curr
Opinions in Nephrology and Hypertension 16:542-546, 2007. Impact factor 4.0
21
70. Mak RH, Cheung W. Adipokines and gut hormones in end-stage renal disease.
Peritoneal Dialysis International 27 Suppl 2:S298-S302, 2007. Impact factor 2.1
71. Mak RH, Cheung W, Roberts CT. The growth hormone-insulin-like growth factor-I axis
in chronic kidney disease. Growth Hormone and IGF Research 18:17-25, 2008. Impact
factor 2.1
72. Mak RH, Wong JH. Are oral antibiotics alone efficacious for treatment of a first episode
of acute pyelonephritis in children? Nature Clinical Practice Nephrology 4:10-11, 2008.
Impact factor 7 .9
73. Mak RH. Insulin and its role in chronic kidney disease. Pediatr Nephrol 23:355-362,
2008. Impact factor 2.9
74. Cheung W, Rosengren S, Boyle DL, Mak RH. Modulation of melanocortin signaling
ameliorates uremic cachexia. Kidney International 74:180-186, 2008. Impact factor 7.9
75. Mak RH. Acute kidney injury in children: the dawn of a new era. Pediatric Nephrology
23:2147-2149, 2008. Impact factor 2.9
76. Mak RH, Cheung W. Transforming growth factors and insulin-like growth factors in
chronic kidney disease. Journal of Organ Dysfunction 5:59-64, 2009.
77. Mak RH. Recent advances in chronic dialysis and renal transplantation in children.
Pediatric Nephrology 24:459-461, 2009. Impact factor 2.9
78. Schwartz GJ, Munoz A, Schneider MF, Mak RH, Kaskel F, Warady BA, Furth S. New
equations to estimate GFR children with CKD. Journal of the American Society of
Nephrology 20:629-637, 2009. Impact factor 7.9
79. Wong C, Pierce CB, Cole SR, Warady BA, Mak RH, Benador NM, Kaskel F, Furth SL,
Schwartz G. Association of proteinuria with race, cause of chronic kidney disease and
glomerular filtration rate in the Chronic Kidney Disease in Children Study. Clinical
Journal of the American Society of Nephrology 4:812-819, 2009. Impact factor 5.2
80. Cheung W, Mak RH. Ghrelin and its analogues as therapeutic agents for anorexia and
cachexia in end-stage renal disease. Kidney International 76:135-137, 2009. Impact
factor 7.9
81. Ingulli E, Mistry K, Mak RH. Acid-base homeostasis. In Pediatric Nephrology 6th Edition,
Volume 1. Editors Avner ED, Harmon WE, Niaudet P, Yoshikawa N Springer pp205-230,
2009.
82. Mak RH, Flynn J, Bakris G. Pediatrics: blood pressure target for renoprotection in
children. Nature Review Nephrology 6:67-68, 2010. Impact factor 7.9
83. Mak RH, Bakris G. Pediatrics: masked hypertension: a risk factor in children with CKD.
Nature Review Nephrology 6:132-134, 2010. Impact factor 7.9
22
84. Cheung WW, Paik KH, Mak RH. Inflammation and cachexia in chronic kidney disease.
Pediatric Nephrology 25:711-724, 2010. Impact factor 2.9
85. Santos F, Kaskel F, Mak RH, Caldas A. 8th International Symposium on Growth and
Nutrition in Children with Chronic Renal Disease. Pediatric Nephrology 25:581-582,
2010. Impact factor 2.9
86. Querfeld U, Mak RH. Vitamin D deficiency and toxicity in chronic kidney disease: in
search of the therapeutic window. Pediatric Nephrology 25:2413-2430, 2010. Impact
factor 2.9
87. Cheung W, Mak RH. Ghrelin in chronic kidney disease. International Journal of Peptides
2010: 2010 pii:567343, Impact factor 1,8
88. Cheung W, Zhang JY, Paik KH, Mak RH. The impact of inflammation on bone mass in
children. Pediatric Nephrology 26:1937-1946, 2011. Impact factor 2.9
89. Mak RH, Ikizler TA, Kovesdy CP, Raj DS, Stenvinkel P, Kalantar-Zadeh K. Wasting in
chronic kidney disease. J Sarcopenia, Cachexia and Muscle 2:9-25, 2011.
90. Mak RH, Cheung WW. Is ghrelin a biomarker for mortality in end-stage renal disease?
Kidney International 79:697-699, 2011. Impact factor 7.9
91. Kalantar-Zadeh K, Cano NJ, Buddle K, Chazot C Kovesdy CP, Mak RH, Mehrotra R, Raj
DS, Sehgal AR, Stenvinkel P, Ikizler TA. Diets and enteral supplements for improving
outcomes in chronic kidney disease. Nature Rev Nephrology 7:369-384, 2011. Impact
factor 2.9
92. Furth SL, Abraham AG, Jerry-Fluker J, Schwartz GJ, Benfield M, Kaskel F, Wong C,
Mak RH, Moxey-Mims M, Warady BA. Metabolic abnormalities, cardiovascular disease
risk factors, and GFR decline in children with chronic kidney disease. Clin J Am Soc
Nephrology 6:2132-2140, 2011. Impact factor 5.2
93. Rees L, Mak RH. Nutrition and growth in children with chronic kidney disease. Nature
Reviews Nephrology 7:615-623, 2011. Impact factor 2.9
94. Mak RH. Serum myostatin in patients on maintenance haemodialysis: a useful biomarker
of muscle wasting? Clinical Endocrinology 75:738-739, 2011. Impact factor 3.9
95. Foster BJ, McCauley L, Mak RH. Nutrition in infants and very young children with chronic
kidney disease. Pediatric Nephrology 27:1427-1439, 2012. Impact factor 2.9
96. Mak RH, Cheung WW, Zhan JY, Shen Q, Foster BJ. Cachexia and protein-energy
wasting in children with chronic kidney disease. Pediatric Nephrology 27:173-181, 2012.
Impact factor 2.9
97. Ishikura K, Hamasaki Y, Sakai T, Hataya H, Mak RH, Honda M. Posterior reversible
encephalopathy syndrome in children with kidney diseases. Pediatr Nephrol 27:375-384,
2012. Impact factor 2.9
23
98. Ingulli E, Fine R, Mak RH. Growth and GH-IGF in chronic kidney disease. The Handbook
of Growth and Growth Monitoring in Health and Disease. Ed. VR Preedy. Publisher:
Springer. Chapter 164, pp 2763-2772, 2012.
99. Mak RH, Cheung WW. MicroRNAs: a new therapeutic frontier for muscle wasting in
chronic kidney disease. Kidney International 82:373-374, 2012. Impact factor 7.9
100. Cheung WW, Mak RH. Melanocortin antagonism ameliorates muscle wasting and
inflammation in chronic kidney disease. American Journal of Physiology Renal
Physiology 303(9):F1315-24, 2012. Impact factor 3.6
101. Carter CE, Shayan K, Mak RH, Yorgin PD, Krous HF. Nephrotic Syndrome in an 18
year-old boy with congenital myelomeningocele. Pediatric Nephrology 28:1963-67, 2013
Impact factor 2.9
102. Mak RH, Warady BA. Vascular access in children: arteriovenous fistula or CVC?
Nature Reviews Nephrology 9:9-11, 2013. Impact factor 7.9
103. Mak RH, Smoyer WE. Nephrotic syndrome: Genetic screening in steroid-resistant
nephrotic syndrome. Nature Reviews Nephroogy 9:379-81, 2013. Impact factor 7.9
104. Gunta S, Mak RH. Leptin and ghrelin pathophysiology in chronic kidney disease.
Pediatric Nephrology 28:841-58, 2013. Impact factor 2.9
105. Gunta SG, Mak RH. Is obesity a risk factor for chronic kidney disease in children?
Pediatric Nephrology 28:1949-1956, 2013. Impact factor 2.9
106. Gunta S, Thadhani R, Mak RH. The effect of vitamin D status on risk factors for
cardiovascular disease. Nature Reviews Nephrology 9:337-347, 2013. Impact factor 7.9
107. Ingulli E, Mak RH. Growth in children with chronic kidney disease: role of nutrition,
growth hormone, dialysis and steroids. Current Opinion in Pediatrics 26: 187-192, 2014.
Impact factor 2.6
108. Abraham AG, Mak RH, Mitsnefes M, White C, Moxey-Mims M, Warady B, Furth SL.
Protein energy wasting in children with chronic kidney disease. Pediatric Nephrology
2014 Feb EPUB Impact factor 2.9
109. Cheung WW, Ding W, Gunta SS, Tabakman R, Klapper LN, Gertler A, Mak RH.
Pegulated leptin antagonist treatment ameliorates CKD-associated cachexia in mice.
Journal of the American Society of Nephrology 25(1):119-28, 2014 Impact factor 8.9
24
ABSTRACTS PRESENTED AT NATIONAL AND INTERNATIONAL MEETINGS
1.
Mak RH, Bakowski M, Haycock GB, Chantler C. Polyamines in children with uremia and
the nephrotic syndrome. Annual meeting of the British Pediatric Association, York,
England, 1981. (oral presentation)
2.
Mak RH, Al-Dahhan J, Haycock GB, Chantler C. Evaluation of different methods of
measuring renal function in children after renal transplantation. Annual meeting of the
European Society of Pediatric Nephrology, Antwerp, Belgium, 1981. International
Journal of Pediatric Nephrology. 1981; 2:144. (poster)
3.
Mak RH, Turner C, Haycock BG, Chantler C. Metabolic and hormonal changes during
constant hyperglycemia in children with uremia. Second International meeting on
Management of Children with Chronic Renal Failure, Heidelberg, Germany, 1982. (oral
presentation)
4.
Mak RH, Turner C, Powell H, Thompson T, Haycock GB, Chantler C. Reversal and
prevention of secondary hyperparathyroidism in children with chronic renal failure.
Annual meeting of the European Society of Pediatric Nephrology, Stockholm, Sweden,
1982. International Journal of Pediatric Nephrology. 1982; 3:131. (oral presentation)
5.
Mak RH, Turner C, Powell H, Haycock GB, Chantler C. Treatment of secondary
hyperparathyroidism by phosphate restriction in children with chronic renal failure. Renal
Association meeting, London, England, May 1982. Kidney International. 1983; 22:410.
(oral presentation)
6.
Mak RH, Turner C, Bettinelli A, Haycock GB, Chantler C. Glucose intolerance in uremia:
Role of secondary hyperparathyroidism. Renal Association meeting, London, England,
October 1982. Kidney International. (oral presentation)
7.
Mak RH, Turner C, Thompson T, Powell H, Haycock GB, Chantler C. Effect of treatment
of secondary hyperparathyroidism on glucose metabolism in patients with uremia. 3rd
International Congress of Nutrition in Renal Disease, Marseilles, France, 1982. (oral
presentation)
8.
Mak RH, Turner C, Thompson T, Haycock GB, Chantler C. Long term follow-up of child
with uremia treated by phosphate restriction. Anglo-French Conference of Pediatric
Nephrology, London, England, 1983. (oral presentation)
9.
Mak RH, Turner C, Thompson T, Powell H, Haycock GB, Chantler C. Treatment of
secondary hyperparathyroidism in children with uremia: Effect on growth, bone disease,
renal function and anemia. Sixth International Congress of Pediatric Nephrology,
Hannover, Germany, 1983. European Journal of Pediatrics. 1983; 140 (2):200. (oral
presentation)
10. Turner C, Mak RH, Thompson T, Dalton N, Haycock BG, Chantler C. Hormonal and
metabolic changes after correction of secondary hyperparathyroidism in children with
25
uremia. Sixth International Congress of Pediatric Nephrology, Hannover, Germany,
1983. European Journal of Pediatrics. 1983; 140 (2):200. (oral presentation)
11. Bettineli A, Mak RH, Turner C, Haycock GB, Chantler C. Renal Tubular handling of
phosphate, sodium and water in children after renal transplantation. Sixth International
Congress of Pediatric Nephrology, Hannover, Germany, 1983. European Journal of
Pediatrics. 1983; 140 (2):191. (oral presentation)
12. Mak RH, Turner C, Thompson T, et al. Suppression of secondary hyperparathyroidism
by phosphate restriction in children with uremia. Renal Association meeting, London,
England, October 1983. (oral presentation)
13. Mak RH, Chantler C. Glucose in uremia: Effect of CAPD. International Meeting of
CAPD in Children, Heidelberg, Germany, May 1984. (oral presentation)
14. Mak RH, Turner C, Haycock GB, Cantler, C. Glucose intolerance in uremia. Renal
Association meeting, London, England, April 1985. (oral presentation)
15. Mak RH, Thompson T, Turner C, Haycock GB, Chantler C. The effect of dietary protein
restriction on glucose metabolism in uremia. British Pediatric Association meeting, York,
England, April 1985. (oral presentation)
16. Mak RH, Chantler C, Turner C, et al. Insulin resistance and secretion in uremic children.
Annual meeting of the European Society of Pediatric Nephrology, Dubrovnic, Yugoslavia,
1985. (oral presentation)
17. Mak RH, Turner C, Thompson T, et al. Glucose metabolism in uremia: Effect of dietary
protein and phosphate. Fourth International Congress of Nutrition in Renal Disease,
Williamsburg, Virginia, 1985. (oral presentation)
18. Mak RH, Vedi S, Compston J, et al. Treatment of hyperparathyroid bone disease by
high dose phosphate binders in uremic children: CaCO 3 improves but AL(OH)3 retards
mineralization. 1st International Symposium on Calcium, Phosphate and Mineral
Nutrition in Children, Hong Kong, 1986. (oral presentation)
19
Turner C, Mak RH, Thompson T, et al. Changes in vitamin D metabolites and bone
histology following phosphorus restriction in uremic children. Renal Association Annual
Meeting, London, England, 1986. (oral presentation)
20. Mak RH, Chantler C. Glucose metabolism and growth in uremia. Society for Pediatric
Research Annual Meeting, Anaheim, California 1987. Ped Res. 1987; 42(4):480A.
(poster symposium)
21. Mak RH. Intravenous 1,25 vitamin D3 restores glucose tolerance, increases insulin
secretion and correct insulin resistance in uremic patients on hemodialysis. Fifth
International Congress of Nutrition in Renal Disease, Strasbourg, France, 1988. (oral
presentation)
26
22. Mak RH. Insulin metabolism in uremia: Effect of parathyroid hormone and vitamin D
metabolites. NIH Symposium on Growth Failure in Renal Disease. Virginia Beach, VA
1989. (oral presentation)
23. Mak RH. Hyperparathyroidism and growth in uremia. 8th International Congress of
Pediatric Nephrology, Toronto, Canada, 1989. (invited speaker, Symposium on uremic
metabolism)
24. Childress L, Lieberman E, Mak RH. Socialized nonaggressive conduct disorder in a
hemodialysis patient induced inadvertently by health care providers. 8th International
Congress of Pediatric Nephrology, Toronto, Canada, 1989. (poster)
25. Mak RH. The acute effects of intravenous 1,25 vitamin D3 on glucose tolerance and
insulin secretion in uremic patients on hemodialysis. American Society of Nephrology,
Annual Meeting, Washington DC, 1989. (poster)
26. Mak RH, Chang SL, Xie HW. 1,25 Dihydroxycholecalciferol reverses insulin resistance
and hypertension in the uremic rat. The Society for Pediatrics Research Annual
Meeting, New Orleans, 1991 (subspecialty platform session, oral presentation)
27. Mak RH, Chang SL, Xie HW. The conscious acutely uremic rat is resistant to the
hypoglycemic action of insulin but sensitive to that of insulin-like growth factor I. 6th
International Congress of Nutrition in Renal Disease, Harrogate, United Kingdom, 1991.
(poster)
28. Mak RH. Reversal of hypertension and insulin resistance by parenteral administration of
1,25 dihydroxyvitamin D3 in rats with reduced renal mass. 6th International Congress of
Nutrition in Renal Disease, Harrogate, United Kingdom, 1991. (oral presentation)
29. Mak RH. Reversal of glucose intolerance and insulin resistance following correction of
anemia by human recombinant erythropoietin therapy in hemodialysis patients. The
Society for Pediatric Research and the American Federation of Clinical Research Annual
Meetings joint subspecialty session, Baltimore, 1992. (oral presentation)
30. Mak RH, Chang SL, Xie HW, Mehls O. The rat with acute renal failure is sensitive to the
hypoglycemic action of IGF-I but resistant to that of insulin. The Society of Pediatric
Research Annual Meeting, Baltimore, 1992. (poster)
31. Mak RH, Chang SL, Xie HW. 1,25 (OH)2D3 corrects insulin resistance and hypertension
in conscious chronically uremic rats. 9th International Congress of Pediatric Nephrology,
Jerusalem, Israel, 1992. (oral presentation)
32. Mak RH. Correction of anemia by erythropoietin reverses insulin resistance and glucose
intolerance in patients on maintenance hemodialysis. 9th International Congress of
Pediatric Nephrology, Jerusalem, Israel, 1992. (poster symposium)
27
33. Mak RH, Chang SL, Xie HW. Presence of insulin resistance but absence of IGF-I
resistance in rats with acute renal failure. 9th International Congress of Pediatric
Nephrology, Jerusalem, Israel, 1992. (poster symposium)
34. Mak RH Role of anemia in the pathogenesis of glucose intolerance and insulin
resistance in rats with chronic renal failure. American Society of Nephrology Annual
Meeting 1993 (poster)
35
Bang P, Tapanainen PJ, Chang S, Muller H, Rosenfeld R, Mak RH The IGF1-IGFBPaxis in chronically uremic 5/6 nephrectomized rats. III International Symposium on
Insulin-like Growth Factors, Sidney 1994 (poster)
36. Mak RH, Rosenfeld R, Sibley R, Chang S, O'Connor M, Huie P, Pak YK. Normalization
of growth failure and insulin-like binding protein abnormalities by growth hormone in
uremic rats. Society for Pediatric Research Annual Meeting 1995 (poster)
37. Mak RH, Jin JH, Hoffman A, Chang S, Baker B, Hintz R, Pak YK. Insulin ameliorates
growth in experimental uremia. Society for Pediatric Research Annual Meeting 1995
(poster)
38. Mak RH, Chang S, Pak YK. Cellular mechanisms of growth failure in uremia.
for Pediatric Research Annual Meeting 1995 (poster)
Society
39. Pak YK, Draksharapu A, Kim PS, Chang S, Mak RH. Gene expression in uremic left
ventricular hypertrophy: Effects of hypertension and anemia. American Society of
Nephrology Annual Meeting 1995 (poster)
40. Kim PS, Pak YP, Mak RH. Methylprednisolone decreases growth responses to growth
hormone, IGF-I and insulin in normal rats but not in rats with chronic renal failure.
American Society of Nephrology Annual Meeting 1995 (poster)
41. Mak RH, Pak YK. IGF-I resistance in epiphyseal chondrocytes of growth retarded
uremic rats. American Society of Nephrology Annual Meeting 1995 (poster)
42. Alfrey EJ, Conley SB, Tanney DC, Mak R, Hammer GB, Orlandi P, Page L, Dafoe DC,
Salvatierra O Jr. Urinary bladder augmentation can be catastrophic. Pacific Coast
Surgical Association Annual Meeting 1996
43
Mak RH, Pak YK, Lee SY Molecular mechanism of growth retardation in chronic renal
failure. Society for Pediatric Research Annual Meeting 1996 (poster symposium)
44. Mak RH. The effect of erythropoietin on insulin, amino acid and lipid metabolism in
uremia. Society for Pediatric Research Annual Meeting 1996 (subspecialty platform
session, oral presentation)
45. Mak RH. Human recombinant erythropoietin corrects insulin and lipid abnormalities in
patients on peritoneal dialysis. American Society of Nephrology Annual Meeting 1996.
(Blue Ribbon Award for Outstanding Abstract)
28
46. Mak RH. Molecular mechanism of IGF-I resistance in epiphyseal chondrocytes from
growth retarded rats with chronic renal failure. American Society of Nephrology Annual
Meeting 1996. (Blue Ribbon Award for Outstanding Abstract)
47. Mak RH, Chang SL, Kim P. Insulin modulates growth and growth plate IGF-I gene
expression in chronic renal failure. Society for Pediatric Research Annual Meeting 1998.
(poster presentation).
48. Mak RH Effect of metabolic acidosis on insulin, lipid and branched-chain amino acids in
uremia. Society for Pediatric Research Annual Meeting 1999. (poster presentation)
49. Walker G, Nagalla S, Gomez P, Mak RH. Molecular mechanism of growth hormone
resistance in a model of uremic growth retardation: differential gene profiling studies.
Endocrine Society Annual Meeting 2000 (oral presentation).
50. Mak RH, Little B, Skoog S, Barry J, Nagalla S. Identification of specific biomarkers in
children with primary vesicoureteric reflux by a proteomics approach. American Society
of Nephrology Annual Meeting 2000 (oral presentation)
51. Walker G, Nagalla S, Mak RH. A functional genomics approach to growth hormone
resistance in experimental uremic growth retardation. American Society of Nephrology
Annual Meeting 2000 (poster presentation)
52. Mak RH, Little B, Skoog S, Barry J, Nagalla S. Proteomics analysis of primary
vesicoureteric reflux. International Congress of Pediatric Nephrology 2001 (oral
presentation).
53. Mak RH, Little B, Skoog S, Barry J, Nagalla S. Genomic and Proteomic analysis of
primary vesicoureteric reflux. Society for Pediatric Research Annual Meeting 2002 (oral
presentation).
54. Cheung W, Marks DL, Yu X, Cone R, Mak RH. The impact of the central melanocortin
system on the cachexia of uremia. American Society of Nephrology Annual Meeting
(poster presentation)
55. Cheung W, Marks DL, Yu X, Cone R, Mak RH. The role of the hypothalamic
melanocortin system in the cachexia of uremia. Society for Pediatric Research Annual
Meeting 2004 (oral presentation).
56. Cheung W, Markison S, Chen C, Foster AV, Marks DL, Mak RH. Amelioration of
uremia-associated cachexia with a peripherally-administered melanocortin receptor-4
antagonist – A novel therapeutic strategy. American Society of Nephrology Annual
Meeting 2005 (poster presentation)
57. Cheung W, Markison S, Chen C, Foster AV, Marks DL,, Mak RH. Peripheral
administration of a novel melanocortin receptor-4 antagonist ameliorates uremic
cachexia. Society for Pediatric Research Annual Meeting 2006 (oral presentation).
29
58. Cheung W, Mak RH. MC-4 receptor antagonism ameliorates uremic cachexia. Society
for Pediatric Research Annual Meeting 2006 (oral presentation).
59. Cheung W, Mak RH.
peripheral mechanism.
presentation).
MC-4 receptor antagonism ameliorates uremic cachexia:
Society for Pediatric Research Annual Meeting 2007 (oral
60. Cheung W, Mak RH. A novel hypothalamic mechanism for uremic osteodystrophy.
American Society of Nephrology Annual Meeting 2007 (oral presentation).
61. Mak RH, Cheung W. Uremic cachexia: differential role of leptin and melanocortin
signaling. Society for Pediatric Research Annual Meeting 2008 (oral presentation).
62. Cheung W, Paik KH, Mak RH. Vitamin D receptor activation amerliorates cachexia and
in chronic kidney disease. Society for Pediatric Research Annual Meeting 2010 (oral
presentation).
63. Cheung W, Paik KH, Mak RH. Paracalitol amerliorates cachexia by suppression of
inflammation in chronic kidney disease. International Pediatric Nephrology Association
Congress 2010 (oral presentation).
64. Cheung W, Paik KH, Mak RH. Vitamin D receptor activation amerliorates cachexia and
muscle wasting in chronic kidney disease. American Society of Nephrology Annual
Meeting 2010 (oral presentation).
65. Mak RH, Cheung W. Vitamin D receptor activation amerliorates cachexia and mortality in
chronic kidney disease. American Society of Nephrology Annual Meeting 2011 (poster
presentation)
66. Shen Q, Cheung W, Mak RH. Ghrelin amerliorates cachexia and inflammation in
chronic kidney disease. Society for Pediatric Research Annual Meeting 2011 (oral
presentation).
67. Cheung W, Ayalon-Soffer M, Mak RH. Peripheral administration of the leptin antagonist
Bl-5040 ameliorates cachexia, muscle wasting and inflammation in mice with chronic
kidney disease. 6th International Congress of Cachexia, Milan 2011 (poster presentation)
68. Cheung W, Mak RH. Vitamin D ameliorates cachexia, inflammation and muscle wasting
in chronic kidney disease. 6th International Congress of Cachexia, Milan 2011 (poster
presentation)
69. Abraham A, Mak RH, Furth S. Protein energy wasting in children with chronic kidney
disease: Do adult diagnostic criteria make sense? 9th International Symposium in
Nutrition and Growth in Chronic Kidney Disease 2012 (oral presentation)
70. Gunta S, Cheung W, Ayalon-Soffer M, Mak RH. Peripheral administration of the leptin
antagonist Bl-5040 ameliorates cachexia and normalizes muscle function in mice with
30
chronic kidney disease. 9th International Symposium in Nutrition and Growth in Chronic
Kidney Disease 2012 (oral presentation)
71. Gunta S, Cheung W, Dalton N, Gu Y, Alverez E, Peterson K, Mak RH. Ghrelin
ameliorates cachexia, cardiovascular complications, inflammation and prolongs survival
in chronic kidney disease. Society for Pediatric Research Annual Meeting 2012 (oral
presentation). American Society of Pediatric Nephrology Trainee Basic Science
Award Winner
72. Gunta S, Cheung W, Mak RH. Bl5040, a leptin receptor antagonist, ameiiorates
cachexia and normalizes muscle function in chronic kidney disease. Society for Pediatric
Research Annual Meeting 2013 (oral presentation). Pediatric Academic Society David
Nathan Basic Science Award Winner.
73. Mak RH, Cheung W, Lieber R. Vitamin D ameliorates cachexia and muscle wasting in
nephropathic cystinosis. Society for Pediatric Research Annual Meeting 2014 (poster
presentation).
31
INVITED LECTURES/SEMINARS
1.
Polyamines in uremia and nephrotic syndrome. Nephrology Seminar in Institute of Child
Health, London, England, 1981.
2.
Hyperparathyroidism and glucose metabolism in uremia.
Institute of Child Health, London, England, 1982.
3.
Amelioration of renal bone disease. British Council Postgraduate Symposium on
Pediatric Nephrology, London, England, 1983.
4.
Glucose metabolism in uremia. Grand Rounds, Department of Pediatrics, Heidelberg
University, Heidelberg, Germany, 1983.
5.
Phosphate binders in uremic children. Research Seminar, Division of Pediatric
Nephrology, University of California, Los Angeles, Los Angeles, California, 1983.
6.
Carbohydrate metabolism in uremia. Nephrology Seminar, Division of Nephrology,
Hospital for Sick Children, Toronto, Canada, 1984.
7.
Energy metabolism in uremia. Research Seminar, Department of Pediatrics, Virginia
Commonwealth University, Richmond, Virginia, 1984.
8.
Juvenile renal osteodystrophy. Grand Rounds, Department of Internal Medicine,
Chinese University of Hong Kong, 1985.
9.
Glucose metabolism in uremia. Grand Rounds, Department of Medicine, University of
California, San Francisco, San Francisco, California, 1986.
Nephrology Seminar in
10. Insulin metabolism in uremia. Research Seminar, Children's Hospital of Los Angeles,
Los Angeles, California, 1986.
11. Phosphorus restriction in uremic children. Research Seminar, Division of Pediatric
Nephrology, University of California, Los Angeles, Los Angeles, California, 1987.
12. Medical suppression of hyperparathyroidism in moderate renal insufficiency. Research
Seminar, Division of Pediatric Nephrology, University of California, San Francisco, San
Francisco, California, 1988.
13. Carbohydrate metabolism in uremia.
Research Seminar, Division of Pediatric
Nephrology, University of California, Los Angeles, Los Angeles, California, 1988.
14. Vitamin D deficiency and insulin resistance.
Research Seminar, Division of
Endocrinology, Department of Medicine, University of Southern California, School of
Medicine, Los Angeles, California,1989.
32
15. Insulin metabolism in uremia: Effect of PTH and vitamin D metabolites. Renal Grand
Rounds, Department of Medicine, University of Southern California School of Medicine,
Los Angeles, California, 1989.
16. Nutrition in Renal Disease. Grand Rounds, Department of Pediatrics, Olive View
Hospital, UCLA School of Medicine, Los Angeles, California, 1990.
17. Human Recombinant Erythropoietin in Pediatric Dialysis Patients.
Children's Hospital of Los Angeles, Los Angeles, California, 1991.
Grand Round,
18. Vitamin D, insulin resistance and hypertension. Research Seminar, Department of
Physiology, University of Southern California School of Medicine, Los Angeles,
California, 1991.
19. Insulin resistance and hypertension: A pathogenetic link in uremia? Pediatric
Nephrology Seminar, Department of Pediatrics, Guy's Hospital Medical School,
University of London, London, England, 1991.
20. Vitamin D and erythropoietin effects on insulin sensitivity and blood pressure in humans
and rats with chronic renal failure. Endocrinology and Diabetes Grand Rounds,
University of Southern California School of Medicine, Los Angeles, California, 1991.
21. Uremic insulin resistance: Effect of anemia.
University of Miami, Miami, Florida, 1992.
Pediatric Nephrology Seminar XIX,
22. Insulin resistance and hypertension in uremia. UCLA Combined Nephrology Research
Series, Wadsworth Veterans Administration Medical Center, Los Angeles, California,
1992.
23. Insulin metabolism in uremia: Effects of vitamin D and anemia, Nephrlogy Grand
Rounds, Department of Internal Medicine, Harbor UCLA Medical Center Los Angeles,
California, 1992.
24. Hypertension in uremia: Relationships with vitamin D and insulin metabolism.
Postgraduate seminar in hypertension, Department of Physiology, University of Southern
California School of Medicine, Los Angeles, California, 1992.
25. Calcium metabolism and hypertension. Nephrology Grand Rounds, Department of
Internal Medicine and Pediatrics, University of California, San Francisco, San Francisco,
California, 1992.
26. Insulin resistance and hypertension in uremia:
Effects of 1,25 (OH) 2D3 and
erythropoietin. Nephrology Research Conference, Department of Medicine, Stanford
University, Stanford, California, 1993.
27. Advances in the treatment of chronic renal failure. Grand Rounds, Department of
Pediatrics, Santa Clara County Hospital, Santa Clara, California, 1993.
33
28. Treatment of chronic renal failure. Grand Rounds, Department of Pediatrics, Stanford
University, Stanford, California, 1993.
29. Nutritional support in renal disease. National symposium on perinatal and pediatric
nutrition, Stanford University, Stanford, California, 1993.
30. Insulin and insulin-like growth factor metabolism in uremia. Nephrology Research
Conference, Department of Medicine, Stanford, California, 1994.
31. Cellular mechanisms of growth failure in uremia. Nephrology Research Conference,
Department of Medicine, Stanford, California, 1995.
32. Molecular mechanisms of IGF-I resistance in uremia. Nephrology Research Conference,
Department of Medicine, Stanford, California, 1996.
33. Molecular mechanism of growth hormone resistance in uremia.
Pediatric Nephrology Symposium, San Francisco, California, 1996.
North California
34. Molecular mechanism of growth failure in chronic renal failure. North America Pediatric
Renal Transplant Cooperative Study West Regional Meeting, New Orleans, 1996.
35. Effect of IGF-I on bone development. American Society of Pediatric Nephrology Annual
Meeting, Washington DC, 1997.
36. Growth retardation in uremia: molecular pathogenesis. North America Pediatric Renal
Transplant Cooperative Study Annual Meeting, Chicago, 1997.
37. Challenging Clinical Case: Lupus Nephritis. Pediatric Grand Rounds, Department of
Pediatrics, Oregon Health Sciences University, 1997.
38. Novel therapies for progressive renal diseases. Pediatric Grand Rounds, Oregon Health
Sciences University, 1998.
39. Molecular advances in the therapy of renal diseases. Pediatric Grand Rounds, Princess
Margaret Hospital, Hong Kong, 1998.
40. Growth disorders in renal disease. Pediatric Grand Rounds, Chinese University, Hong
Kong, 1998.
41. Advances in therapy of chronic renal disease. Pediatric Grand Rounds, University of
Hong Kong, 1998.
42. Growth Retardation in Chronic Renal Diseases.
Nephrology Symposium, Hong Kong, 1999.
Plenary Lecture, Asian Pediatric
43. Hemolytic uremic syndrome. Pediatric Grand Round, Queen Elizabeth Hospital, Hong
Kong, 1999.
34
44. Reverse genomics in the study of renal diseases. Western Pediatric Nephrology
Symposium, Portland, Oregon, 1999.
45. Growth hormone resistance in uremia.
Plenary Lecture, International Pediatric
Nephrology Association Conference, Valencia, Venezuela, 1999.
46. Insulin, amino-acid and lipid metabolism in uremia. Plenary symposium, International
Pediatric Nephrology Association Conference, Valencia, Venezuela, 1999.
47. Hypertension in Childhood. Pediatric Grand Rounds, Sacred Heart Hospital, Eugene,
Oregon, 1999.
48. Challenging Clinical Case: Renal Artery Stenosis. Pediatric Grand Rounds, Department
of Pediatrics, Oregon Health Sciences University, 2000.
49. Proteomics and genomics in pediatric nephrology research. Western Pediatric
Nephrology Symposium, San Francisco, California, 2001.
50. Differential gene and protein expression in primary ureteric reflux. Invited lecture.
International Developmental Renal Biology Workshop, Victoria, Canada, 2001.
51. The role of cytokine and leptin signaling in the cachexia of chronic renal failure. Western
Pediatric Nephrology Symposium, Seattle, Washington, 2002.
52. Genetic basis of primary vesico-ureteral reflux.
Research Seminar, Division of
Nephrology and Hypertension, Oregon Health and Science University, 2002.
53. Leptin and Renal Disease. Western Society of Pediatric Nephrology Annual Meeting,
Seattle, Washington, 2002.
54. Genomic and proteomic analysis of primary vesico-ureteral reflux. Pediatric Nephrology
Seminar XXX, University of Miami, Florida, 2003.
55. The role of neuropeptide signaling in the cachexia of chronic renal failure. American
Society of Pediatric Nephrology Annual Meeting, Seattle, 2003.
56. The impact of leptin and neuropeptide signaling on nutrition in chronic renal disease.
Pediatric Nephrology Seminar XXXI, University of Miami, Florida, 2004.
57. Nutrition in chronic kidney disease: Role of diet and cytokines. International Pediatric
Nephrology Congress, Adelaide, Australia, 2004.
58. Nutrition and growth in chronic kidney disease. Western Society of Pediatric Nephrology
Annual Meeting, Vancouver, Canada, 2004
59. The pathogenesis of primary vesico-ureteral reflux. Is there a big bang? American
Society of Nephrology Annual Meeting, St Louis, 2004.
35
60. Vesico-ureteral reflux: Pathogenesis and biomarker discovery. International Society of
Nephrology Global Education Update Conference in Dubai, 2004.
61. Focal Segmental Glomerulsclerosis: An update on pathogenesis and therapeutic
strategies. International Society of Nephrology Global Education Update Conference in
Dubai, 2004.
62. Genetics of Steroid Resistant Nephrotic Syndrome. Pediatric Nephrology Seminar XXXII,
University of Miami, Florida, 2005.
63. Pathophysiology of anorexia and cachexia in uremia.
Meeting, Portland, Oregon, 2005
Northwest Renal Dietitian’s
64. Pathogenesis of steroid resistant nephrotic syndrome: therapeutic implications. Pediatric
Nephrology Seminar, Hong Kong, 2005.
65. Cytokine signaling and nutrition in uremia. Nephrology Seminar, University of Hong
Kong. 2005.
66. Leptin, melanocortin and uremic cachexia. Invited Lecture, Recent Advances in Basic
Nephrology, World Congress of Nephrology, Singapore, 2005.
67. Leptin signaling in chronic kidney disease. Western Society of Pediatric Nephrology
Annual Meeting, Honolulu, Hawaii, 2005.
68. Biomarker discovery in ureteral reflux, Renal Grand Rounds, Royal Melbourne Hospital,
Australia, 2005.
69. Molecular mechanisms of urinary tract infections and renal scarring. Pediatric Grand
Rounds, University of New South Wales, Australia, 2005.
70. Molecular and genetic basis of reflux. nephropathy Asian Pediatric Nephrology Seminar,
Beijing, China, 2005.
71. Leptin signaling in chronic kidney disease: implications for nutrition and growth. Keynote
speaker, Canadian Pediatric Nephrology Association Annual Meeting, Philadelphia,
2005.
72. Molecular pathogenesis of veisoureteral reflux.
University of Miami, 2006.
Pediatric Nephrology Symposium,
73. Mechanisms of uremic cachexia. Pediatric Nephrology Research Seminar. Hospital for
Sick Children, Great Ormond Street, University of London, 2006.
74. Update on IgA Nephropathy. South Africa Nephrology Symposium, Capetown, 2006.
36
75. Genetic and molecular basis of reflux nephropathy. International Pediatric Nephrology
Association Review Course, Fudan University Shanghai 2006.
76. Molecular pathogenesis and novel therapy for focal segmental glomeruloscloersis.
International Pediatric Nephrology Association Review Course, Fudan University
Shanghai 2006.
77. Nutrition in chronic kidney disease in children. International Pediatric Nephrology
Association Review Course, Fudan University Shanghai 2006.
78. Leptin and melanocortin signaling in uremia-associated cachexia. Symposium on
“Inflammation and Uremic Pathophysiology” ASPN/Pediatric Academic Societies Annual
Meeting, San Francisco, 2006.
79. Nutritional challenges in chronic kidney disease in children. International Pediatric
Nephrology Association Dialysis and Transplantation Review Course, Princess Margaret
Hospital, Hong Kong, 2006.
80. Adipokines and gut hormones in the regulation of nutrition in uremia.
Society of Peritoneal Dialysis Congress, Hong Kong, 2006.
International
81. Molecular mechanism of growth retardation in chronic kidney disease. Western Society
of Pediatric Nephrology Annual Meeting, Albuquerque, New Mexico, 2006.
82. Weight regulation in chronic kidney disease: the flipside of obesity. University of Miami
Pediatric Nephrology Seminar, Miami, 2007.
83. Obesity as a factor in the progression of kidney disease. University of Miami Pediatric
Nephrology Seminar, Miami, 2007.
84. Nutrition and growth in chronic kidney disease.
Association Teaching Course Beijing, 2007.
International Pediatric Nephrology
85. Obesity and kidney disease. International Pediatric Nephrology Association Teaching
Course Beijing, 2007.
86. Weight regulation and chronic kidney disease: the flipside of obesity.
Rounds, Baylor University, 2007.
Renal Grand
87. Weight regulation in chronic kidney disease: cachexia and obesity. Pediatric Nephrology
Seminar. Metropolitan Children’s Hospital, Tokyo, 2007.
88. A novel central mechanism for renal osteodystrophy. Symposium on bone disease.
ASPN/Pediatric Academic Societies Annual Meeting, Toronto, 2007.
89. Nutrition update for ESRD. Dialysis Symposium, International Pediatric Nephrology
Association Congress, Budapest, Hungary 2007.
37
90. Genomic and proteomic analysis of ureteric reflux. International Pediatric Nephrology
Association Congress, Budapest, Hungary 2007.
91. Melanocortin Signaling in Chronic Kidney Disease: Novel therapeutic indications.
American Society of Nephrology Annual Meeting, invited talk, Philadelphia, 2008.
92. Obesity and Chronic Kidney Disease Overview. ASPN/PAS Annual Meeting, Baltimore,
2009.
93. Inflammation and nutrition in chronic kidney disease. 8th Symposium on Growth and
Nutrition in Children with Chronic Renal Disease. Oveido, Spain. May 25-31, 2009.
94. The impact of melanocortin signaling on bone mass regulation in chronic kidney disease.
8th Symposium on Growth and Nutrition in Children with Chronic Renal Disease. Oveido,
Spain. May 25-31, 2009.
95. Energy homeostasis and muscle wasting in cystinosis: role of inflammation.
2nd International Cystinosis Research Symposium. Newport Beach, CA. April, 2010.
96. Obesity and the Kidney. Western Society of Pediatric Nephrology Meeting. Pasadena,
CA. April, 2010.
97. Growth retardation and muscle wasting in cystinosis. Cystinosis Research Foundation
symposium. Newport Beach, CA. May, 2010.
98. Impact of leptin signaling on bone mass in health and disease. International Pediatric
Nephrology Association Congress, New York. September, 2010.
99. Non-skeletal effects of vitamin D deficiency in chronic kidney disease. Western Society
of Pediatric Nephrology Annual Meeting, San Diego. February, 2011.
100. Muscle wasting in nephropathic cystinosis.
Symposium, Newport Beach. April, 2011.
Cystinosis Research Foundation
101. Cachexia and obesity in chronic kidney disease. International Symposium on Nutrition
and Growth. Heidelberg, Germany. May, 2011.
102. Cutting-edge advances and novel therapies in Pediatric Nephrology. Latin American
Pediatric Nephrology Annual Conference. Sao Paulo, Brazil. October, 2011.
103. The current approach to pediatric hypertension. Grand Rounds Presentation, Scripps
Mercy Hospital, San Diego, CA. November, 2011.
104. Failure to thrive and renal cachexia: from pediatrics to geriatrics. International Cachexia
Conference. Milan, Italy. December, 2011.
105. Cachexia in Chronic Kidney Disease. Oregon State University, January, 2012.
38
106. Cystinosis 2012: an update. Pediatric Nephrology Seminar, University of Miami, March,
2012.
107. Vitamin D and its role in diabetes mellitus. Pediatric Nephrology Seminar, University of
Miami, March, 2012.
108. Vitamin D and muscle wasting in nephropathic cystinosis. 3 rd International Cystinosis
Research Symposium. Newport Beach, CA. April, 2012.
109. Cachexia and Obesity in children with chronic kidney disease. 9th International
Symposium on Nutrition and Growth in CKD. San Diego, CA. April, 2012.
110. Ghrelin in chronic kidney disease. Western Society of Pediatric Nephrology Annual
Meeting, Vancouver. June, 2012.
111. Weight regulation in chronic kidney disease. Chinese University of Hong Kong invited
seminar. Hong Kong, June, 2012.
112. Cachexia in CKD: from pediatrics to geriatrics. International symposium on nutrition and
metabolism in renal disease. Hawaii. June, 2012.
113. The role of ghrelin in muscle wasting, cardiovascular complications and survival in
chronic kidney disease. International symposium on nutrition and metabolism in renal
disease. Hawaii. June, 2012.
114. Urinary tract infections, an update. Grandrounds at Scripps Mercy Hospital, San Diego,
March 2013.
115. Muscle wasting and inflammation in nephropathic cystinosis.
Foundation Conference, Newport Beach, April 2013.
Cystinosis Research
116. Cachexia in chronic kidney disease: An inflammatory process. International Pediatric
Nephrology Association Congress, Shanghai, China, September 2013.
117. Weight regulation and mortality risk in chronic kidney disease.
September, 2013.
118. The impact of obesity on chronic kidney disease.
Annual Meeting, Atlanta, November 2013.
Fudan University.
American Society of Nephrology
119. Cachexia in chronic kidney disease: an update. International Cachexia Congress. Kobe,
Japan, December 2013.
39
120. Energy homeostasis and muscle wasting in nephropathic cystinosis: Role of vitamin D
and inflammation. Cystinosis International Symposium, Irvine, March 2014.
121. Vitamin D and muscle wasting in cystinosis.
Symposium, Newport Beach, April 2014
40
Cystinosis Research Foundation

Download Report